Ublituximab Completed Phase 2 Trials for Multiple Sclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02738775Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis